



PERSONALIZED
MEDICINE COALITION

MEMBERSHIP PROSPECTUS

The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.



PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE OR NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on that assumption, some 20 institutions representing different sectors of the health care system launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across multiple stakeholders, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient. By combining the data from those tests with an individual's medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans.

PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

- **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers about how the field can make the health system more effective and efficient by targeting better treatments to only those patients who will benefit.
- **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.
- **Evidence Development:** To encourage the swifter adoption of personalized medicine by health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

– Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

• **Public Policy Committee**

- Patient Advocacy Organization Working Group
- Pharma and Diagnostics Working Group
- Intellectual Property Working Group

• **Science Policy Committee**

- Clinical Integration Working Group
- Value Assessment Working Group
- Information Management Working Group

• **Pharmacogenomics Working Group**

MEMBER BENEFITS

**Contact
2,000+**

leaders in personalized medicine via PMC's member database

**Interact with
200+**

thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

**Save
40%**

on registration for the Annual Personalized Medicine Conference

Attend Member Meetings and Events

at no charge

Discounted Subscription Offers

for outlets including *GenomeWeb*, *STAT News*, and *The Journal of Precision Medicine*

Receive Copies

of PMC publications and reports

PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES

Invitae
Laboratory Corporation of America (LabCorp)
Quest Diagnostics

DIAGNOSTIC COMPANIES

Adaptive Biotechnologies
Admera Health
Agendia NV
Agilent Technologies
Alacris Theranostics GmbH
Almac Diagnostics
Asuragen
Caprion Proteomics
Caris Life Sciences
CareDx, Inc.
Circulogene
Clarigent Health
Cofactor Genomics
Diaceutics
Exact Sciences
Foundation Medicine, Inc.
GeneCentric Therapeutics
Grail
Guardant Health
MolecularMD
Myriad Genetics
NanoString Technologies
Olaris Therapeutics
Personalis
QIAGEN, Inc.
Roche Diagnostics
RxGenomix
Scipher Medicine
Siemens Healthcare Diagnostics, Inc.
SomaLogic, Inc.
Thrive
Zionexa US Corporation

EMERGING BIOTECH/ PHARMACEUTICAL COMPANIES

Aperiomics
Freenome

Immatics US
Legend Biotech
PAREXEL
Regeneron
Tango Therapeutics
WuXi NextCode

HEALTH INSURANCE COMPANIES

Harvard Pilgrim Health Care

INDUSTRY/TRADE ASSOCIATIONS

American Clinical Laboratory Association
BIO (Biotechnology Innovation Organization)
Biocom
PhRMA

IT/INFORMATICS COMPANIES

2bPrecise
Change Healthcare
DNAnexus
Flatiron Health
GNS Healthcare
M2Gen
Medidata
P4-ML
PierianDx
Salutary, Inc.
Syapse
Translational Software
XIFIN, Inc.

LARGE BIOTECH/ PHARMACEUTICAL COMPANIES

AbbVie
Amgen, Inc.
Astellas Pharma Global Development
AstraZeneca Pharmaceuticals
Bausch Health Companies
Bayer
Biogen
Bristol-Myers Squibb

Eli Lilly and Company
Genentech, Inc.
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Takeda Pharmaceuticals, Inc.

NUTRITION, HEALTH & WELLNESS COMPANIES

Preventive Partners

PATIENT ADVOCACY GROUPS

Accelerated Cure Project for Multiple Sclerosis
Alliance for Aging Research
Alzheimer's Foundation of America
Asian & Pacific Islander American Health Forum
Bulgarian Association for Personalized Medicine
Canadian Organization for Rare Disorders
Clarity Foundation
Colorectal Cancer Alliance
CureDuchenne
Emily's Entourage
EveryLife Foundation For Rare Diseases
Fight Colorectal Cancer
Friends of Cancer Research
GO₂ Foundation for Lung Cancer
Global Liver Institute
HealthyWomen
International Cancer Advocacy Network ("ICAN")
LUNGeivity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health

National Alliance for
Hispanic Health
National Health Council
National Patient
Advocate Foundation
OpenOme
Team Trevor

PERSONALIZED MEDICINE SERVICE PROVIDERS

Coriell Life Sciences
Genome Medical
Helix
Intervention Insights
Michael J. Bauer, M.D.,
& Associates, Inc.
Sema4
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS

American Association
for Cancer Research
(AACR)
American Medical
Association (AMA)
Arizona State University
Association for
Molecular Pathology
(AMP)
Baylor Health Care
System Precision
Medicine Institute
Brown University
Business Finland
Cancer Treatment
Centers of America
Cello Health
BioConsulting
College of American
Pathologists
Colorado Center for
Personalized Medicine
CommonSpirit Health
Coriell Institute for
Medical Research
CREATE Health
Translational Cancer
Centre, Lund
University
Dasman Diabetes
Institute
Duke Center for
Research on
Personalized Health
Care

Essentia Institute of
Rural Health
European Infrastructure
for Translational
Medicine
Genome British
Columbia
Genome Canada
Harvard Business School
Hospital Albert Einstein
Instituto de Salud
Carlos III
Intermountain
Healthcare
Johns Hopkins
Individualized Health
King Faisal Specialist
Hospital and Research
Centre
MaineHealth
Accountable Care
Organization
Manchester University
School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson
– Institute for
Personalized Cancer
Therapy
MITRE Corporation
Moffitt Cancer Center
National Pharmaceutical
Council
Nicklaus Children's
Hospital Research
Institute
North Carolina
Biotechnology Center
NorthShore University
HealthSystem
Precision Health
Initiative at
Cedars-Sinai
Qatar Biobank
Quebec Network
for Personalized
Health Care
Sanford Imagenetics,
Sanford Health
Shenandoah University
Swedish Cancer
Institute
The Christ Hospital
The Jackson Laboratory
Thomas Jefferson
University
Translational Genomics
Research Institute

UC Davis Mouse Biology
Program
University of Alabama,
Birmingham
University of California,
San Francisco (UCSF)
University of
Pennsylvania Health
System
University of Rochester
University of South
Florida Morsani
College of Medicine
Vanderbilt University
Medical Center
West Cancer Center

RESEARCH TOOL COMPANIES

Illumina, Inc.
Thermo Fisher Scientific

STRATEGIC PARTNERS

Alva10
Arnold & Porter
Artisan Healthcare
Consulting
Bioscience Valuation
BSV GmbH
Blue Latitude Health
Boston Healthcare
Associates
Bradford Power
Bruce Quinn Associates
Cambridge Healthtech
Institute
Center for Individual
Opportunity
ConText
ConvergeHEALTH
by Deloitte
Defined Health
Dr. Alana Maria Lelo
EdgeTech Law, LLP
EY Parthenon
Foley & Lardner, LLP
Foley Hoag, LLP
Genome Creative
Goldbug Strategies,
LLC
Health Advances, LLC
Hogan Lovells, LLP
Innovation Horizons
Innovation Policy
Solutions
Jane Binger, Ed.D.

Jared Schwartz, M.D.,
Ph.D., LLC
L.E.K. Consulting
McDermott Will
& Emery
Neil A. Belson, LLC
Ogilvy
S.D. Averbuch
Consulting, LLC
Slone Partners

*The Journal of
Precision Medicine*
Truc Nguyen, M.D., Ph.D.
United States
Pharmacopeial
Convention (USP)
W20
Wildtype Advisors
William P. Stanford,
M.D., Ph.D.

VENTURE CAPITAL
GreyBird Ventures, LLC
Health Catalyst Capital
Management, LLC
Kleiner Perkins
Caufield & Byers
Section 32
Third Rock Ventures,
LLC

DUES STRUCTURE

As of January 2020

Large Public Corporation	\$29,000
Small Public Corporation	\$14,500
Trade Association	(based on revenues)
Private Corporation >50 FTEs	\$5,775
Professional Society	\$5,775
Private Corporation <50 FTEs	\$3,500
Strategic Partner	\$2,900
Research, Education & Clinical Care Institutions	\$2,900
Sole Proprietor	\$1,150
Patient Advocacy Group	\$500

Visit pmc.portal.membersuite.com to join the Coalition.

For more information, contact Kayla Smith,
Director, Membership & Development, at
ksmith@personalizedmedicinecoalition.org
or 202-589-0070.

STAFF

Edward Abrahams, Ph.D.
President

Cynthia A. Bens
*Senior Vice President,
Public Policy*

Daryl Pritchard, Ph.D.
*Senior Vice President,
Science Policy*

Faswillla Sampson, M.S.
Vice President, Operations

Christopher J. Wells, M.P.A.
Vice President, Public Affairs

Kayla Smith
*Director, Membership &
Development*

David L. Davenport
*Manager, Public Policy; Secretary
to the Board*

Lindsay Stephens
Senior Operations Coordinator

BOARD OF DIRECTORS

Jay G. Wohlgemuth, M.D.
Board Chair
Quest Diagnostics

William S. Dalton, Ph.D., M.D.
Board Vice Chair
M2Gen

Mark P. Stevenson, M.B.A.
Board Treasurer
Thermo Fisher Scientific

Michael Pellini, M.D., M.B.A.
Board Secretary
Section 32

Bonnie J. Addario
GO₂ Foundation for Lung Cancer

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for
Translational Medicine (EATRIS)

Randy Burkholder
PhRMA

Stephen L. Eck, M.D., Ph.D.
Immatics US

Lori Frank, Ph.D.
Alzheimer's Foundation
of America

Brad Gray
NanoString Technologies

Kris Joshi, Ph.D.
Change Healthcare

Anne-Marie Martin, Ph.D.
Novartis

Howard L. McLeod, Pharm.D.

J. Brian Munroe
Bausch Health Companies

Lincoln Nadauld, M.D., Ph.D.
Intermountain Healthcare

Kimberly J. Popovits

Hakan Sakul, Ph.D.
Pfizer, Inc.

**Michael S. Sherman, M.D.,
M.B.A., M.S.**
Harvard Pilgrim Health Care

**Apostolia M. Tsimberidou,
M.D., Ph.D.**
MD Anderson Cancer Center

Michael Vasconcelles, M.D.
Flatiron Health

Werner Verbiest
Johnson & Johnson



**PERSONALIZED
MEDICINE COALITION**

1710 Rhode Island Ave., NW, Suite 700
Washington, DC 20036

P: 202.589.1770

pmc@personalizedmedicinecoalition.org